Ranbaxy Laboratories has got sanction from the US Food and Drug Administration (USFDA) to produce and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 75 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths.

Hyderabad: Cipla Ltd will produce the primary three-in-one cocktail anti-AIDS medicine used for children. This accompanies the USFDA clearing a combining quantity of Boehringer Ingelheim’s Viramune, GlaxoSmithKline’s Epivir (or lamivudine) and Bristol-Myers Squibb’s Zerit (or stavudine), which are anti-retrovirals or drugs that fight back AIDS.

The commendation came under the US President’s Emergency Plan for AIDS Relief, or Pepfar, a $15 billion, 5-year plan to clash the threat in over 15 countries.

In afternoon trading, Alembic is quoting at Rs 73.90, up Rs 4.70, or 6.79%.

In afternoon trading (3:06 pm), Alembic is hovering near Rs 68.80, up R

Mumbai: Ohm Laboratories, Ranbaxy’s US subsidiary has received the US Food and Drug

Cadila Healthcare lost 3.65% to Rs 337 tracking powerless international market, regardless of reports it is near to getting hold of a mid-sized Spanish pharmaceutical company for $30 million.

In the meantime, the BSE Sensex was down 349.87 points to 14,751.23, chasing after fresh setback in worldwide markets. Asian stocks collapsed across the board as credit jitters erupted after France’s largest listed bank BNP Paribas on 9 August, blocked three funds, which invested in US subprime mortgages.

There were 5276 shares of the scrip for trading on the BSE counter, and the average daily volume of the stock stood at 24,996 shares in the last one quarter.